TABLE 1.

Specific adverse events of clinical interest with BTK inhibitors

	Rates with Ibrutinib (RESONATE/phase 3 ELEVATE RR/phase 3 ALPINE)	Rates with acalabrutinib (phase 3 ASCEND/phase 3 ELEVATE RR)	Rates with zanubrutinib (phase 1/phase 3 ALPINE)
Atrial fibrillation	12%/16%/10.1%	5%/9.4%	1%/2.5%
Hypertension	21%/22.8%/13%	3%/8.6%	5.3%/15.7%
High‐grade bleeding	10%/5.3%/3.9%	1%/4.5%	1%/2.9%
Neutropenia (grade 3+)	25%/22.8%/15%	15%/19.5%	6.4%/18.6%
Infections (grade 3+)	45%/30.0%/17.9%	15%/30.8%	NR/12.7%

Note: Median follow‐up differs on these trials: RESONATE‐median 65 months; ELEVATE RR‐ median 40.9 months; ALPINE‐median 15 months; ASCEND—16.1 months; phase 1 zanubrutinib—13.7 months.

Abbreviation: NR, not reported.